Benedetta Pellegrino is a medical oncologist working at the University Hospital of Parma. She is Breast Cancer specialist certified by the Ulm University and the European School of Oncology. In 2017, she took part at the “Workshop of Methods in Clinical Cancer Research” where she was trained to plan and conduct clinical trials and she has recently published the “Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic TNBC” as first author. Thanks to the ESMO fellowship program, she had the chance to work at “Vall d’Hebron Institute of Oncology” to receive specialized training in translational research in breast cancer, through the collaboration of home and host institutes and under the mentorship of Dr. Serra. Thus, she became involved in the preclinical and clinical validation of the functional biomarker of HRD, named RAD51 assay. She is sub-investigator of more than 20 clinical trials and co-authors of more than 20 articles (10 as first author).
Last update: June 2021